A company trying to bring back the woolly mammoth just got a valuation offer that would make most Wall Street CFOs blink twice.
Colossal Biosciences — yes, the "de-extinction" startup — is reportedly in talks to raise fresh capital at a $20 billion to $30 billion valuation.
That's not a typo.
That's roughly triple its last valuation.
Sixteen months ago, this company was worth $10.2 billion.
Back then, the headline was dire wolves.
Literally.
Colossal had just unveiled Romulus and Remus — pups engineered from 72,000-year-old dire wolf DNA.
Today those "extinct" wolves are fully grown, over 120 lbs each, hunting in packs with a third wolf named Khaleesi.
Stay with me — because the wolves aren't even the business.
Here's the twist most headlines miss.
Colossal isn't just chasing Jurassic Park fantasies.
It's quietly building a biotech empire around the tools it invented to make de-extinction possible:
For a company once dismissed as a sci-fi vanity project, revenue changes the conversation entirely.
Colossal has already:
👉 Sold conservation tech to the U.S. government
👉 Landed a $60 million investment from the UAE
👉 Floated a future revenue stream through biodiversity credits — think carbon credits, but for bringing species back
This raise isn't happening in a vacuum.
It's landing right in the middle of a boom in longevity tech, deep-tech, and alternative science bets.
Investors aren't just betting on mammoths roaming Siberia again.
They're betting that the science built to resurrect the past can quietly rewrite the future of fertility, conservation, and biology itself.
That's a bet worth billions.
That's all for now!
